101 related articles for article (PubMed ID: 19779801)
1. HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A.
Abe K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
Arch Virol; 2009; 154(10):1671-7. PubMed ID: 19779801
[TBL] [Abstract][Full Text] [Related]
2. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.
Yang F; Robotham JM; Nelson HB; Irsigler A; Kenworthy R; Tang H
J Virol; 2008 Jun; 82(11):5269-78. PubMed ID: 18385230
[TBL] [Abstract][Full Text] [Related]
3. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
[TBL] [Abstract][Full Text] [Related]
4. Diverse effects of cyclosporine on hepatitis C virus strain replication.
Ishii N; Watashi K; Hishiki T; Goto K; Inoue D; Hijikata M; Wakita T; Kato N; Shimotohno K
J Virol; 2006 May; 80(9):4510-20. PubMed ID: 16611911
[TBL] [Abstract][Full Text] [Related]
5. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.
Goto K; Watashi K; Inoue D; Hijikata M; Shimotohno K
Cancer Sci; 2009 Oct; 100(10):1943-50. PubMed ID: 19659609
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
[TBL] [Abstract][Full Text] [Related]
7. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.
Robida JM; Nelson HB; Liu Z; Tang H
J Virol; 2007 Jun; 81(11):5829-40. PubMed ID: 17376913
[TBL] [Abstract][Full Text] [Related]
8. Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro.
Weng L; Tian X; Gao Y; Watashi K; Shimotohno K; Wakita T; Kohara M; Toyoda T
Biochim Biophys Acta; 2012 Dec; 1820(12):1886-92. PubMed ID: 22954804
[TBL] [Abstract][Full Text] [Related]
9. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.
Yang F; Robotham JM; Grise H; Frausto S; Madan V; Zayas M; Bartenschlager R; Robinson M; Greenstein AE; Nag A; Logan TM; Bienkiewicz E; Tang H
PLoS Pathog; 2010 Sep; 6(9):e1001118. PubMed ID: 20886100
[TBL] [Abstract][Full Text] [Related]
10. Replication of a novel subgenomic HCV genotype 1a replicon expressing a puromycin resistance gene in Huh-7 cells.
Liang C; Rieder E; Hahm B; Jang SK; Paul A; Wimmer E
Virology; 2005 Mar; 333(1):41-53. PubMed ID: 15708591
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
Madan V; Paul D; Lohmann V; Bartenschlager R
Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.
Watashi K; Hijikata M; Hosaka M; Yamaji M; Shimotohno K
Hepatology; 2003 Nov; 38(5):1282-8. PubMed ID: 14578868
[TBL] [Abstract][Full Text] [Related]
13. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype.
Namba K; Naka K; Dansako H; Nozaki A; Ikeda M; Shiratori Y; Shimotohno K; Kato N
Biochem Biophys Res Commun; 2004 Oct; 323(1):299-309. PubMed ID: 15351737
[TBL] [Abstract][Full Text] [Related]
14. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.
Ciesek S; Steinmann E; Wedemeyer H; Manns MP; Neyts J; Tautz N; Madan V; Bartenschlager R; von Hahn T; Pietschmann T
Hepatology; 2009 Nov; 50(5):1638-45. PubMed ID: 19821520
[TBL] [Abstract][Full Text] [Related]
16. Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1).
Miyamoto M; Kato T; Date T; Mizokami M; Wakita T
Intervirology; 2006; 49(1-2):37-43. PubMed ID: 16166787
[TBL] [Abstract][Full Text] [Related]
17. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.
Goto K; Watashi K; Murata T; Hishiki T; Hijikata M; Shimotohno K
Biochem Biophys Res Commun; 2006 May; 343(3):879-84. PubMed ID: 16564500
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.
Fernandes F; Poole DS; Hoover S; Middleton R; Andrei AC; Gerstner J; Striker R
Hepatology; 2007 Oct; 46(4):1026-33. PubMed ID: 17600342
[TBL] [Abstract][Full Text] [Related]
20. Targeting lipid metabolism in the treatment of hepatitis C virus infection.
Amemiya F; Maekawa S; Itakura Y; Kanayama A; Matsui A; Takano S; Yamaguchi T; Itakura J; Kitamura T; Inoue T; Sakamoto M; Yamauchi K; Okada S; Yamashita A; Sakamoto N; Itoh M; Enomoto N
J Infect Dis; 2008 Feb; 197(3):361-70. PubMed ID: 18248300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
